BioPharmX completed enrollment of 225 patients with moderate to severe inflammatory, non-nodular acne vulgaris in the double-blind, placebo-controlled, U.S. Phase IIb OPAL trial evaluating about 1 g of 1% or 2% BPX-01 topical gel once...

Final data from 24 acne patients in the per protocol (PP) population of a double-blind, U.S. Phase IIa trial showed that once-daily 1% topical BPX-01 significantly reduced mean P. acnes bacteria from baseline to week...

BioPharmX began the double-blind, placebo-controlled, U.S. Phase IIb OPAL trial to evaluate about 1 g of 1% or 2% BPX-01 topical gel once daily for 12 weeks in about 225 patients with moderate to severe...

Top-line data from a double-blind, placebo-controlled, U.S. Phase IIa trial in 30 patients showed that once-daily 1% BPX-01 topical gel significantly reduced P. acnes bacteria from baseline to week 4. BioPharmX also said there were...

BioPharmX completed enrollment of 30 patients in a double-blind, placebo-controlled, U.S. Phase IIa trial evaluating once-daily BPX-01 1% topical gel for 4 weeks. BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif.   Product: BPX-01   Business: Dermatology...

BioPharmX began a double-blind, placebo-controlled Phase IIa trial of topical BPX-01 in about 30-35 patients. BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif.   Product: BPX01   Business: Dermatology   Molecular target: NA   Description: Topical formulation...